MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis

Blood

Volumn 107, Issue 11, 2006, Pages 4549-4553

  Lunghi, Paolo ^a   Costanzo, Antonio ^b   Salvatore, Luigi ^b   Noguera, Nelida ^b   Mazzera, Laura ^b   Tabilio, Antonio ^b   Lo Coco, Francesco ^b   Levrero, Massimo ^b   Bonati, Antonio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ARSENIC TRIOXIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN P53; PROTEIN P73;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

EID: 33744496269     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2829     Document Type: Article

References (33)

1. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.
2. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H. How acute promyelocytic leukaemia revived arsenic. Nat Cancer Rev. 2002;2:705-713.
3. Ravandi F. Arsenic trioxide: expanding roles for an ancient drug? Leukemia. 2004;18:1457-1459.
4. Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood. 2004;104:519-525.
5. Jing Y, Wang L, Xia LJ, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001;97:264-269.
6. Diaz Z, Colombo M, Mann KK, et al. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood. 2005;105:1237-1245.
7. Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG, Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia. 2005;19:234-244.
8. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851-859.
9. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-819.
10. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2:605-615.
11. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 2002;18:90-95.
12. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian p53-related protein that can induce apoptosis. Nature. 1997;389:191-194.
13. Gong J, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806-809.
14. Agami R, Blandino G, Oren M, et al. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature. 1999;399:809-813.
15. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560-564.
16. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J Exp Med. 1998;188:1763-1768.
17. Pozniak CD, Radinovic S, Yang A, et al. An antiapoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000;289:304-306.
18. Grob TJ, Novak U, Maisse C, et al. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213-1223.
19. Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62:636-641.
20. Stiewe T, Zimmermann S, Frilling A, et al. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 2002;62:3598-3602.
21. Rizzo MG, Giombini E, Diverio D, et al. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia. 2004;18:1804-1809
22. Hu G, Zhang W, Deisseroth AB. p53 gene mutations in acute myelogenous leukaemia. Br J Haematol. 1992;81:489-494.
23. Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RH, Herrmann F. Mechanisms of p53 alteration in acute leukemias. Leukemia. 1994;8:1673-1681.
24. Soenen V, Preudhomme C, Roumier C, Daudignon A, Lai JL, Fenaux P. 17p deletion acute myeloid leukemia and myelodysplastic syndrome: analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008-1015.
25. Nakano Y, Naoe T, Kiyoi H, et al. Prognostic value of p53 gene mutations and product expression in de novo acute myeloid leukemia. Eur J Haematol. 2000;65:23-31.
26. Cartron PF, Gallenne T, Bougras G, et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell. 2004;16:807-818.
27. Melino G, Bernassola F, Ranalli M, et al. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem. 2004;279:8076-8083.
28. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849-862.
29. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell. 2002;9:175-186.
30. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer S. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285-291.
31. Ottilie S, Diaz JL, Horne W, et al. Dimerization properties of human BAD. J Biol Chem. 1997;272:30866-30872.
32. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res. 2002;62:2883-2889.
33. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol. 2003;23:5540-5555.